Stage 2 Stocks in Drug Manufacturers - Specialty & Generic
26 US stocks in Drug Manufacturers - Specialty & Generic are in Stage 2, the advancing phase of Weinstein's stage analysis. Listed below: those priced at $5 or more and trading at least $1 million a day on average, ranked by setup score and updated after every close (last close Oct 23, 2026).
| Stock | Close | 1D | Setup | Weeks in stage |
|---|---|---|---|---|
| XERS Xeris Biopharma Holdings, Inc. | $10.20 | -6.08% | 9.4 | 14 |
| PCRX Pacira BioSciences, Inc. | $36.42 | +0.22% | 9.2 | 2 |
| BHC Bausch Health Companies Inc. | $6.44 | -0.77% | 6.6 | 6 |
| AMRX Amneal Pharmaceuticals, Inc. Class A | $20.38 | -0.49% | 6.5 | 20 |
| AMPH Amphastar Pharmaceuticals, Inc. | $25.14 | -3.46% | 6.4 | 4 |
| KNSA Kiniksa Pharmaceuticals International, plc Class A | $76.73 | -5.03% | 6.3 | 73 |
| VTRS Viatris Inc. | $18.00 | -2.60% | 6.3 | 56 |
| PRGO Perrigo Company plc | $15.96 | -2.50% | 6.0 | 7 |
| TEVA Teva Pharmaceutical Industries Limited | $39.41 | -1.99% | 5.7 | 10 |
| ANIK Anika Therapeutics Inc. | $21.42 | +1.56% | 5.7 | 15 |
| TAK Takeda Pharmaceutical Company Limited | $20.24 | -0.59% | 5.6 | 11 |
| HCM HUTCHMED (China) Limited | $14.36 | +0.56% | 5.6 | 2 |
| AMLX Amylyx Pharmaceuticals, Inc. | $27.20 | -4.80% | 4.8 | 16 |
| TKNO Alpha Teknova, Inc. | $6.42 | +4.39% | 4.8 | 18 |
| TRLV Trulieve Cannabis Corp. Subordinate Voting Shares | $10.42 | -4.58% | 4.5 | 11 |
| KMDA Kamada Ltd. | $7.77 | +0.52% | 4.5 | 5 |
| EOLS Evolus, Inc. | $7.01 | -5.40% | 4.3 | 18 |
| ETON Eton Pharmaceuticals, Inc. | $50.00 | -0.04% | 4.3 | 30 |
Drug Manufacturers - Specialty & Generic: quick answers
Which stocks in Drug Manufacturers - Specialty & Generic are in an uptrend?
As of Oct 23, 2026, 26 US stocks in Drug Manufacturers - Specialty & Generic are in Stage 2, the uptrend phase. The largest by market value are Takeda Pharmaceutical, Teva Pharmaceutical Industries, Viatris, Amneal Pharmaceuticals and Kiniksa Pharmaceuticals International.
How many stocks in Drug Manufacturers - Specialty & Generic are in Stage 2?
26 of the 84 stocks we track in Drug Manufacturers - Specialty & Generic (30.9%) are in Stage 2. 10 are basing in Stage 1, 13 are topping in Stage 3 and 34 are in a Stage 4 downtrend. That share has fallen 4.8 points over the last 20 sessions.
Which stocks in Drug Manufacturers - Specialty & Generic entered Stage 2 recently?
3 stocks entered Stage 2 in the last four weeks: Pacira BioSciences (week 2), HUTCHMED (China) (week 2) and Amphastar Pharmaceuticals (week 4).
Daily screens
Every one recalculated after the close, with the exact criteria published on the page.
Stage 2 in other sectors & industries
US stocks in a confirmed uptrend (Stage 2, Weinstein’s advancing phase), grouped by sector and industry and ranked by setup score.